High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Plasmodium falciparum resistance to series of anti-malarial drugs is a major challenge in efforts to control and/or eliminate malaria globally. In 1998, following the widespread of chloroquine (CQ) resistant P. falciparum , Ethiopia switched from CQ to sulfadoxine–pyrimethamine (SP) and subsequently in 2004 from SP to artemether–lumefantrine (AL) for the treatment of uncomplicated falciparum malaria. Data on the prevalence of CQ resistance markers after more than two decades of its removal is important to map the selection pressure behind the targets codons of interest. The present study was conducted to determine the prevalence of mutations in Pfcrt K76T and Pfmdr1 N86Y codons among malaria-infected patients from Adama, Olenchiti and Metehara sites of East Shewa zone, Oromia Regional State, Ethiopia. Methods: Finger-prick whole blood samples were collected on 3MM Whatman ® filter papers from a total of 121 microscopically confirmed P. falciparum infected patients. Extraction of parasite DNA was done by Chelex-100 method from dried blood spot (DBS). Genomic DNA template was used to amplify Pfcrt K76T and Pfmdr1 N86Y codons by nested PCR. Nested PCR products were subjected to Artherobacter protophormiae-I ( APoI ) restriction enzyme digestion to determine mutations at codons 76 and 86 of Pfcrt and Pfmdr1 genes, respectively. Results: Of 83 P. falciparum isolates successfully genotyped for Pfcrt K76T, 91.6% carried the mutant genotypes (76T). The prevalence of Pfcrt 76T was 95.7%, 92.5% and 84.5% in Adama, Metehara and Olenchiti, respectively. The prevalence of Pfcrt 76T mutations in three of the study sites showed no statistical significance difference (χ 2 = 1.895; P = 0.388). On the other hand, of the 80 P. falciparum samples successfully amplified for Pfmdr1 , all carried the wild-type genotypes ( Pfmdr1 N86). Conclusion: Although CQ officially has been ceased for the treatment of falciparum malaria for more than two decades in Ethiopia, greater proportions of P. falciparum clinical isolates circulating in the study areas carry the mutant 76T genotypes indicating the presence of indirect CQ pressure in the country. However, the return of Pfmdr1 N86 wild-type allele may be favoured by the use of AL for the treatment of uncomplicated falciparum malaria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“we confirmed previous reports of wild-type mdr1 N86 near fixation [44,51,52].”
From High prevalence and emerging positive association of kelch13 R622I and HRP2-based RDT negativity in Plasmodium falciparum in northern Ethiopia (2025) · cites this paper as [51]
In the citing paper
“The widespread PfMDR1 NFSND haplotype (93.0%), consistent with reports from Ethiopia35,36,53 and across Africa54,55, further complicates resistance dynamics.”
From Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia (2026) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nega, D., Dana, D., Tefera, T., & Eshetu, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123630 · Cited by 86
Research works printed but not linked: 45
- WHO. World Malaria Report 2021. Geneva: World Health Organization; 2021.
- Roux AT, Maharaj L, Oyegoke O, Akoniyon OP, Adeleke MA, Maharaj R, et al. Chloroquine and sulfadoxine–pyrimethamine resistance in sub-Saharan Africa—a review. Front Genet. 2021;12:668574. · DOI
- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein Pfcrt and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861–71. · doi:10.1016/s1097-2765(05)00077-8 · Paper page
- Djimde A, Pharm D, Ogobara K, Doumbo MD, Joseph F, et al. A molecular marker for chloroquine resistant falciparum malaria. N Ingl J Med. 2001;344:257–63. · DOI · Paper page
- Ibrahim ML, Steenkste N, Khim N, Adam HH, Konate L, Coppee JY, et al. Field-based evidence of fast and global increase of Plasmodium falciparum drug resistance by DNA-microarrays and PCR/RFLP in Niger. Malar J. 2009;8:32. · DOI
- Golassa L, Kamugisha E, Ishengoma DS, Baraka V, Shayo A, Baliraine FN, et al. Identification of large variation in Pfcrt, Pfmdr-1 and Pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania. Malar J. 2015;14:264. · DOI
- Ikegbunam MN, Nkonganyi CN, Thomas BN, Esimone CO, Velavan TP, Ojurongbe O. Analysis of Plasmodium falciparum Pfcrt and Pfmdr1 genes in parasite isolates from asymptomatic individuals in Southeast Nigeria 11 years after withdrawal of chloroquine. Malar J. 2019;18:343. · DOI
- Shrivastava SK, Gupta RK, Mahanta J, Dubey ML. Correlation of molecular markers, Pfmdr1-N86Y and Pfcrt-K76T, with in vitro chloroquine resistant Plasmodium falciparum, isolated in the malaria endemic states of Assam and Arunachal Pradesh, Northeast India. PLoS ONE. 2014;9:e103848. · doi:10.1371/journal.pone.0103848
- Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gna N, Uhlemann A, et al. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016;7:11553. · DOI · Paper page
- Singh G, Singh R, Urhekar AD, Rane K. Gene sequence polymorphisms mutations in Pfmdr-1 and Pfcrt-o genes of Plasmodium falciparum. Int J Curr Microbiol Appl Sci. 2016;5:451–8. · doi:10.20546/ijcmas.2016.510.051
- Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. Antimalarial drug resistance: literature review and activities and findings of the ICEMR Network. Am J Trop Med Hyg. 2015;93:57–68. · DOI · Paper page
- Tulu AN, Webbeg RH, Schellenberg AJS, Bradley DJ. Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R Soc Trop Med Hyg. 1996;44:556–7. · DOI · Paper page
- Hailemeskel E, Menberu T, Shumie G, Behaksra S, Chali W, Keffale M, et al. Prevalence of Plasmodium falciparum Pfcrt and Pfmdr1 alleles in settings with different levels of Plasmodium vivax co-endemicity in Ethiopia. Int J Parasitol Drugs Drug Resist. 2019;11:8–12. · DOI · Paper page
- Heuchert A, Abduselam N, Zeynudin A, Eshetu T, Loscher T, Wieser A, et al. Molecular markers of anti-malarial drug resistance in Southwest Ethiopia over time: regional surveillance from 2006 to 2013. Malar J. 2015;14:208. · doi:10.1186/s12936-015-0723-2
- Mekonnen SK, Aseffa A, Berhe N, Teklehaymanot T, Clouse RM, Gebru T, et al. Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia. Malar J. 2014;13:244. · DOI · Paper page
- Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870–5. · DOI · Paper page
- Ketema T, Bacha K, Getahun K, Del Portillo HA, Bassat Q. Plasmodium vivax epidemiology in Ethiopia 2000–2020: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2021;15:e0009781. · DOI · Paper page
- Golassa L, White MT. Population – level estimates of the proportion of Plasmodium vivax blood-stage infections attributable to relapses among febrile patients attending Adama Malaria Diagnostic Centre. Malar J. 2017;16:307. · doi:10.1186/s12936-017-1944-3
- File T, Chekol T, Solomon G, Dinka H, Golassa L. Detection of high frequency of MAD20 allelic variants of Plasmodium falciparum merozoite surface protein 1 gene from Adama and its surroundings, Oromia, Ethiopia. Malar J. 2021;20:385. · doi:10.1186/s12936-021-03914-9
- Atrosh WM, Al-Mekhalfi HM, Mahdy MAK, Surin J. The detection of Pfcrt and Pfmdr1 point mutations as molecular markers of chloroquine drug resistance, Pahang, Malaysia. Malar J. 2012;11:251. · DOI
- Mulenga MC, Sitali L, Ciubotariu II, Hawela MB, Hamainza B. Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia. Malar J. 2021;20:329. · doi:10.1186/s12936-021-03859-z
- Fontecha G, Pinto A, Archaga O, Betancourth S, Escober L, Henríquez J, et al. Assessment of Plasmodium falciparum anti-malarial drug resistance markers in Pfcrt and Pfmdr1 genes in isolates from Honduras and Nicaragua, 2018–2021. Malar J. 2021;20:465. · doi:10.1186/s12936-021-03977-8
- Veiga MI, Ferreira PE, Gil PJ. Multiplex PCR-RFLP methods for Pfcrt, Pfmdr1 and Pfdhfr mutations in Plasmodium falciparum. Mol Cell Probes. 2006;20:100–4. · DOI
- Mula P, Fernandez-martinez A, Lucio A, De, Ramos JM, Reyes F, Gonzalez V, et al. Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in Southern Ethiopia. Malar J. 2011;10:214. · DOI
- Jaleta F, Garoma G, Gerenfes T. Evaluation of malaria microscopy diagnosis performance in public hospitals of Eastern and Central part of Oromia Region, Ethiopia, 2019. Pathol Lab Med Int. 2020;12:1–8. · doi:10.2147/plmi.s259159
- Schunk M, Kumma WP, Miranda IB, Osman ME, Roewer S, Alano A, et al. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in Southern Ethiopia. Malar J. 2006;5:54. · DOI
- Yobi DM, Kayiba NK, Mvumbi DM, Boreux R, Kabututu PZ, Situakibanza HNT, et al. Molecular surveillance of anti-malarial drug resistance in Democratic Republic of Congo: high variability of chloroquine resistance and lack of amodiaquinoresistance. Malar J. 2020;19:121. · doi:10.1186/s12936-020-03192-x
- Al-Mekhlafi AM, Mahdy MAK, Al-Mekhlafi HM, Azazy AA, Fong MY. High frequency of Plasmodium falciparum chloroquine resistance marker (Pfcrt T76 mutation) in Yemen: an urgent need to re-examine malaria drug policy. Parasit Vectors. 2011;4:94. · DOI
- Adam R, Mukhtar MM, Abubakar UF, Damudi HA, Muhammad A, Ibrahim SS. Polymorphism analysis of Pfmdr1 and Pfcrt from Plasmodium falciparum isolates in Northwestern Nigeria revealed the major markers associated with antimalarial resistance. Diseases. 2021;9:6. · DOI
- Das S, Tripathy S, Chattopadhayay S, Das B, Kar Mahapatra S, Hati AK, et al. Progressive increase in point mutations associates chloroquine resistance: even after withdrawal of chloroquine use in India. IJP Drugs Drug Resist. 2017;7:251–61. · doi:10.1016/j.ijpddr.2017.06.002
- Johora FT, Elahi R, Nima MK, Hossain MS, Rashid H, Kibria MG, et al. Persistence of markers of chloroquine resistance in Plasmodium falciparum in Bangladesh. Am J Trop Med Hyg. 2021;104:276–82. · DOI
- Ebel ER, Reis F, Petrov DA, Beleza S. Historical trends and new surveillance of Plasmodium falciparum drug resistance markers in Angola. Malar J. 2021;20:175. · DOI
- Bwire GM, Ngasala B, Mikomangwa WP, Kilonzi M, Kamuhabwa AAR. Detection of mutations associated with artemisinin resistance at K13- propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania. Sci Rep. 2020;10:3500. · doi:10.1038/s41598-020-60549-7
- Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergent SB, et al. Assessment of molecular markers of anti-malarial drug resistance among children participating in a therapeutic efficacy study in Western Kenya. Malar J. 2020;19:291. · DOI
- Balikagala B, Sakurai-Yatsushiro M, Tachibana SI, Ikeda M, Yamauchi M, Katuro OT, et al. Recovery and stable persistence of chloroquine sensitivity in Plasmodium falciparum parasites after its discontinued use in Northern Uganda. Malar J. 2020;19:76. · doi:10.1186/s12936-020-03157-0
- Afoakwah R, Boampong JN, Egyir-Yawson A, Nwaefuna EK, Verner ON, Asare KK. High prevalence of PfCRT K76T mutation in Plasmodium falciparum isolates in Ghana. Acta Trop. 2014;136:32–6. · doi:10.1016/j.actatropica.2014.03.030
- Edogun HA, Daramola GO, Ojerinde AO, Esan CO, Adegbuyi AT. Prevalence of mutant alleles responsible for chloroquine resistance among Plasmodium falciparum isolates in North Central, Nigeria. J Adv Biol Biotechnol. 2019;20:1–8. · doi:10.9734/jabb/2018/v20i330078
- Lo E, Hemming-schroeder E, Yewhalaw D, Nguyen J, Kebede E, Zemene E, et al. Transmission dynamics of co-endemic Plasmodium vivax and Plasmodium falciparum in Ethiopia and prevalence of anti-malarial resistant genotypes. PLoS Negl Trop Dis. 2017;11:e0005806. · DOI
- Otienoburu SD, Maiga-Ascofare O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of Plasmodium falciparum Pfcrt and Pfmdr1 polymorphisms after treatment with artesunate–amodiaquine fixed dose combination or artemether–lumefantrine in Liberia. Malar J. 2016;15:452. · doi:10.1186/s12936-016-1503-3
- Asare KK, Africa J, Mbata J, Opoku YK. The emergence of chloroquine-sensitive Plasmodium falciparum is influenced by selected communities in some parts of the Central Region of Ghana. Malar J. 2021;20:447. · doi:10.1186/s12936-021-03985-8
- Chidimatembue A, Svigel SS, Mayor A, Aide P, Nhama A, Nhamussua L, et al. Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018. Malar J. 2021;20:398. · doi:10.1186/s12936-021-03930-9
- Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Bjorkman A, et al. Plasmodium falciparum drug resistance phenotype as assessed by patient antimalarial drug levels and its association with Pfmdr1 polymorphisms. J Infect Dis. 2013;207:842–7. · DOI
- Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Price RN, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for Plasmodium falciparum malaria after artemether–lumefantrine and artesunate–amodiaquine. Am J Trop Med Hyg. 2014;91:833–43. · DOI · Paper page
- Dimbu PR, Horth R, Candido LM, Ferreira M, Caquece F. Continued low efficacy of artemether–lumefantrine in Angola in 2019. Antimicrob Agents Chemother. 2021;65:e01949-20. · doi:10.1128/aac.01949-20
- Adamu A, Jada MS, Haruna HMS, Yakubu BO, Ibrahim MA, Balogun EO, et al. Plasmodium falciparum multidrug resistance gene-1 polymorphisms in Northern Nigeria: implications for the continued use of artemether–lumefantrine in the region. Malar J. 2020;19:439. · doi:10.1186/s12936-020-03506-z
Cited by
Zeleke, A. J., Fola, A. A., Tollefson, G. A., Niaré, K., Leonetti, A., Taropawala, O., Marglous, J., Crudale, R., Brhane, B. G., Assefa, A., et al. (2025) · PLOS Pathogens · doi:10.1371/journal.ppat.1013771 · Cited by 12
Letebo, A., Vanheer, L. N., Engdaw, M., Ejigu, L. A., Hailu Alemayehu, D., Deressa, J. D., Adnew, B., Ayele, A., Bezabih, M. K., Demisse, M., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02420-5 · Cited by 4
Metadata
- Authors
- Hassen, J., Alemayehu, G. S., Dinka, H., & Golassa, L.
- Venue
- Malaria Journal
- Published
- 2022-10-07
- Volume
- 21
- Issue
- 1
- ISSN
- 1475-2875
- Cited by
- 32
- References
- 1
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia. https://app.cochat.ai/papers/10.1186/s12936-022-04304-5
- The paper
- Hassen, J., Alemayehu, G. S., Dinka, H., & Golassa, L. (2022). High prevalence of Pfcrt 76T and Pfmdr1 N86 genotypes in malaria infected patients attending health facilities in East Shewa zone, Oromia Regional State, Ethiopia. Malaria Journal. https://doi.org/10.1186/s12936-022-04304-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.